Navigation Links
New report illustrates persistent global burden of anemia among high-risk populations
Date:12/2/2013

(WASHINGTON, December 2, 2013) Despite increasing efforts to diagnose and treat anemia worldwide, there remains a surprisingly large global burden of the disease, particularly among young children and women, according to a new report on trends in anemia between 1990 and 2010. The report was published online today in Blood, the Journal of the American Society of Hematology.

Anemia is a complex condition characterized by a low level of hemoglobin, the protein that binds to oxygen in the lungs and carries it to all parts of the body. A low level of hemoglobin leads to impaired delivery of oxygen to the body and causes symptoms including weakness, fatigue, and difficulty concentrating. Symptoms of anemia in children may include impaired mental or motor development.

Historical estimates on the global prevalence of anemia vary widely based on either inconsistent data or the incorrect assumption that anemia is always caused by iron deficiency. Disease prevalence is consistently higher in individuals of low socioeconomic status, those considered to be underweight, and females who have recently given birth. Some estimates suggest that as many as 50-80 percent of individuals in these high-risk populations may have some degree of anemia.

"While we know that anemia is highly prevalent, it has been difficult to quantify the true global burden of this disease without over-counting or duplicating occurrences based on the range of likely causes," said lead study author Nicholas Kassebaum, MD, of the Institute for Health Metrics and Evaluation at the University of Washington in Seattle. "In addition, previous studies have been geographically limited and have lacked detail about the disease's severity or cause."

Seeking to create the first comprehensive audit of the global burden of anemia, Kassebaum and colleagues conducted an analysis of anemia data from a large global study (the Global Burden of Diseases, Injuries and Risk Factors Study) aiming to more accurately calculate the burden of disease worldwide. The team reviewed data on the 17 most common causes of anemia cases from 187 countries between 1990 and 2010 to calculate the total prevalence and disability burden rates (reported as years lived with disability, or YLD, which captures the average duration and relative severity of the disease). Anemia disease burden was defined based on hemoglobin deficiency using standard thresholds that varied by sex, age, and pregnancy status. As the analysis did not include all anemia-related comorbidities, the actual burden of disease associated with anemia may be higher.

Overall, the report found that while the global prevalence of anemia decreased between 1990 and 2010 (from 40.2% to 32.9%), the disease remains responsible for a significant burden on society, with an increase in global YLDs from 65.5 million to 68.4 million over the 20-year period. By comparison, this global disease burden is greater than burden associated with major depression (63.2 million YLDs), chronic respiratory diseases (49.3 million YLDs), and general injuries (47.2 million YLDs).

Though the overall prevalence of anemia decreased during the study period (from 40.2% in 1990 to 32.9% in 2010), the burden among children under age 5 actually increased. This age group accounted for more cases of anemia than any other age group and had the highest severity of disease in low- and middle-income regions. In addition to the difference in prevalence and burden related to age, data gathered by investigators also indicate a widening gender gap in anemia burden over time. While prevalence decreased in both genders between 1990 and 2010, the changes were more pronounced for males, while female prevalence remained higher in most regions and age groups.

Data from the report also indicate stark differences in the burden of anemia throughout different parts of the world. Data indicate a reduction in anemia burden between 1990 and 2010, particularly in East, South, and Southeast Asia. Yet over the same time period, total anemia YLDs increased in other regions such as the lower income regions of Sub-Saharan Africa.

"While many advances have been made to combat anemia worldwide, these results demonstrate that this disease remains highly burdensome," said Dr. Kassebaum. "Further, our study confirms that young children and women continue to carry the greatest burden, underscoring a need for these groups to remain priorities for anemia control interventions. Our hope is that these findings help encourage the facilitation of new strategies to help begin to reduce this burden, particularly in these high-risk populations."


'/>"/>

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. BCC Research Publishes A New Report On Global Markets For Waste And Wastewater Treatment
2. Hemodialysis Industry for Global and China 2013 Analysis in New Research Report at ChinaMarketResearchReports.com
3. European Home Healthcare Market (Respiratory Therapy, Rehabilitation Therapy) worth $57.2 Billion by 2017 - New Report by MarketsandMarkets
4. New Report Outlines Upcoming Changes to the Medicare Star Ratings Program
5. Cosmetic & Beauty Products Manufacturing in the US Industry Market Research Report from IBISWorld Has Been Updated
6. Wireless Platforms Market Worth $155.2 Billion by 2016 - New Report by MarketsandMarkets
7. Well Intervention (Logging and Bottom Hole Survey) Market Worth $17.48 Billion by 2018 - New Report by MarketsandMarkets
8. Asia-Pacific Nuclear Medicine/Radiopharmaceutical Market Worth $825 Million By 2017 - New Report by MarketsandMarkets
9. China Large Volume Parenteral (LVP) Industry Report, 2013-2015: Worldwide Market Share, Investment Trends, Growth, Size, Strategy and Forecast Research Report
10. ZyDoc Links Philips SpeechExec Enterprise to MediSapien Structured Reporting and Analytics for Radiology at RSNA 2013
11. Europe Seed Treatment (Chemical & Non-Chemical) Market worth $633.2 Million By 2018 - New Report by MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: